Donanemab, Eli Lilly’s New Groundbreaking Alzheimer’s Drug
![brain scans](/sites/g/files/oketem336/files/styles/3_2_480x320/public/media/images/magnetic-resonance-imaging-PR8UWRY_web.jpg.webp?itok=hAsCV9YM)
Dr. Keith Vossel, Neurologist and Director of the UCLA Mary S. Easton Center for Alzheimer’s Research and Care, was interviewed by MarketWatch on May 3, 2023, about his perception of a new groundbreaking Alzheimer’s medication, donanemab, by Eli Lilly, and on the unknown costs associated with the new drug and related tests.